Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-08
2005-02-08
Witz, Jean C. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C514S016700, C530S326000, C530S327000, C530S329000, C424S077000
Reexamination Certificate
active
06852695
ABSTRACT:
A water soluble extract ofM.charantianamed MC6, methods for its preparation and methods for its use in the treatment of hyperglycemic disorders are provided. The active MC6 is characterized by moving as a single band on SDS-PAGE having a molecular weight of less than 10 kDal, and by comprising three peptides. Also provided is a peptide component of MC6 named MC6.1, as well as analogues and mimetics thereof. The active MC6, MC 6.1, MC6.2, and MC6.3 exhibit hypoglycemic activity, even following oral administration. Also provided are methods of using the active agents to treat hyperglycemic disorders, particularly diabetes, where the active agents are preferably orally administered.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853914 (1974-12-01), Goldstein
patent: 3905654 (1975-09-01), Tribe
patent: 3945988 (1976-03-01), Khann et al.
patent: 4043989 (1977-08-01), Schneider et al.
patent: 4069105 (1978-01-01), Singh et al.
patent: 4156081 (1979-05-01), Singh et al.
patent: 4368149 (1983-01-01), Masuho et al.
patent: 4985248 (1991-01-01), Liu
patent: 5086043 (1992-02-01), Liu
patent: 5098710 (1992-03-01), Liu
patent: WO9311155 (1993-06-01), None
patent: WO9716728 (1997-05-01), None
Wopfner er al., “Analysis of 27 Mammalian and 9 Avian PrPs Reveals High Conservation of Flexible Regions of the Prion Protein” (Jun. 25, 1999) J. Mol. Biol., 289(5), 1163-1178.*
van Rheede et al., “Molecular Evolution of the Mammalian Prion Protein” (Jan. 2003) 20(1), 111-121.*
Stahl, et al., Biochem., 32:1991-2002 (1993).
Rudinger “Peptide Hormones”, Parsons J.A., editor (1976) (Univ. park press: Baltimore, MD) p. 1-7.
Akhtar et al, Planta Med., 42:205-212 (1981.
Ali et al, Planta Med., 59:408-412 (1993).
Aslam et al, Lancet, 1:607 (1979).
Baldwa et al, Upsala J. Med. Sci., 82:39-41 (1977).
DiColo, Biomaterials, 13:850-856 (1992).
Driscoll et al, J. Mol. Bio., 232:342-350 (1993).
Dubey et al, Fitoterapia, 58(6):387-39 (1987).
El-Gengaihi et al, Bull. Natl. Res. Cent., 21(3):269-276 (1996).
Hales et al, Biochem. J., 88:137 (1963).
Harrison's “Principles of Internal Medicine”, 11th ed., Braunwald et al, ed., McGrall Hill Book Co, NY 1987.
Heller, CRC Critical Reviews in Therapeutic Drug Carrier Systems, vol. 1, “Biodegradable Polymers in Controlled Drug Delivery”, CRC Press, Boca Raton, FL, pp 39-60 (1987).
Kadish et al, Clin. Chem., 14:116 (1968).
Karunanayake et al, J. Ethnopharmacol., 11(2):223-232 (1984).
Khanna et al, J. Natural Products, 42(6):684 (1979).
Khanna et al, “Hypoglycemic Activity of Polypeptide-p from a Plant Source”, 20th Annual Meeting of the American Society of Pharmacoloby, Purdue Univ., West Lafayette, Jul. 29-Aug. 3, 1979, in J. Nat. Prod (1981) 44(6), 648-655.
Ng et al, The American J. of Chinese Medicine, 15(1-2):31-42 (1987).
Lei et al, J. Tradit. Chin. Med., 52(2):99-106 (1985).
Pugazhenthi et al, Indian J. Clin. Biochem., 11(2):115-119 (1996).
Raman et al, Phytomedicine, 2(4):349-362 (1996).
Reza-Ul-Jalil et al, J. Bangladesh Acad. Sci., 10(1):25-30 (1986).
Sambrook et al, Molecular cloning: A Laboratory Manual, pp. V-XXXII CSHL Press, Cold Spring Harbor, NY 2nd ed. (1989).
Sarkar et al, Pharmacol. Res., 33:104 (1996).
Shibib et al, Biochem. J., 292:267-270 (1993).
De Gioia, Luca et al. “Conformational Polymorphism of the Amyloidogenic and Neurotoxic Peptide Homologous to Residues 106-126 of the Prion Protein”The Journal of Biological Chemistry269:11 (Mar. 18, 1994) 7859-7862.
Leatherdale, B. A. et al. “Improvemeny in Glucose Tolerance Due to Momordica Charantia (Karela)”British Medical Journal 282:6279(Jun. 6, 1981) 1823-1824.
Pugazhenthi, S. et al. “Purification of Three Orally Active Hypoglycemic Compounds Kakara IB, IIIA and IIIB From the Unripe Fruits of Momordica Charantia Linn (Bitter Gourd)” Indian Journal of Clinical Biochemistry 11:2 (1996) 115-119.
Medicherla Satyanarayana
Nag Bishwajit
Sharma Somesh D.
Hanley Susan
Mayer Brown Rowe & Maw LLP
Theracos, Inc.
Witz Jean C.
LandOfFree
Orally active fraction of momordica charantia, active... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Orally active fraction of momordica charantia, active..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally active fraction of momordica charantia, active... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486073